United Therapeutics Corporation (UTHR) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
United Therapeutics Corporation cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $313,600,000.00Net income → Operating adjustments reconciliation: $19,400,000.00Share-based compensation expense → Operating adjustments reconciliation: $43,400,000.00Deferred income taxes → Operating adjustments reconciliation: $25,700,000.00Other → Operating adjustments reconciliation: $24,800,000.00Depreciation and amortization → Operating adjustments reconciliation: $24,200,000.00Accounts receivable → Operating adjustments reconciliation: $1,700,000.00Operating adjustments reconciliation → Other assets and liabilities: $104,100,000.00Operating adjustments reconciliation → Inventories: $17,700,000.00Operating adjustments reconciliation → Net unrealized losses on equity securities: $13,400,000.00Operating adjustments reconciliation → Accounts payable and accrued expenses: $4,000,000.00Proceeds from the exercise of stock options → financing reconciliation: $126,300,000.00financing reconciliation → Net cash from financing activities: $122,400,000.00financing reconciliation → Payments of debt issuance costs: $3,400,000.00financing reconciliation → RSUs withheld for taxes: $500,000.00Maturities of available-for-sale debt securities → investing reconciliation: $265,300,000.00investing reconciliation → Net cash from investing activities: $87,500,000.00investing reconciliation → Purchases of property, plant, and equipment: $108,000,000.00investing reconciliation → Purchases of available-for-sale debt securities: $69,100,000.00investing reconciliation → Deposits: $700,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $1,279,700,000.00Net cash from operating activities → Cash sources and uses: $313,600,000.00Net cash from financing activities → Cash sources and uses: $122,400,000.00Net cash from investing activities → Cash sources and uses: $87,500,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $1,803,200,000.00Net income: $333,000,000.00Net income+$333.00 MDepreciation and amortization: $24,200,000.00Depreciation & amortization+$24.20 MShare-based compensation expense: $43,400,000.00Stock-based compensation+$43.40 MOther: $24,800,000.00Other non-cash items+$24.80 MAccounts receivable: $1,700,000.00Accounts receivable+$1.70 MInventories: -$17,700,000.00Inventories−$17.70 MAccounts payable and accrued expenses: -$4,000,000.00Payables & accrued liabilities−$4.00 MOther assets and liabilities: -$104,100,000.00Other working capital, net−$104.10 MNet unrealized losses on equity securities: -$13,400,000.00Unrealized equity gain & loss−$13.40 MDeferred income taxes: $25,700,000.00Deferred income taxes+$25.70 MImpairment of property, plant, and equipment: $0.00Net cash from operating activities: $313,600,000.00Operating cash+$313.60 MOperating adjustments reconciliation: $139,200,000.00Payments to repurchase common stock: $0.00Proceeds from line of credit: $0.00Repayment of line of credit: $0.00Excise tax paid on net share repurchase: $0.00Payments of debt issuance costs: -$3,400,000.00Debt issuance costs−$3.40 MProceeds from the exercise of stock options: $126,300,000.00Stock option exercises+$126.30 MProceeds from the issuance of stock under ESPP: $0.00RSUs withheld for taxes: -$500,000.00Stock-award tax withholding−$500.00 KNet cash from financing activities: $122,400,000.00Financing cash+$122.40 Mfinancing reconciliation: $126,300,000.00Purchases of property, plant, and equipment: -$108,000,000.00PP&E purchases−$108.00 MDeposits: -$700,000.00Deposits−$700.00 KPurchases of available-for-sale debt securities: -$69,100,000.00AFS securities purchases−$69.10 MMaturities of available-for-sale debt securities: $265,300,000.00AFS securities maturities+$265.30 MSales of available-for-sale debt securities: $0.00Purchase of investment in privately held company: $0.00Net cash from investing activities: $87,500,000.00Investing cash+$87.50 Minvesting reconciliation: $265,300,000.00Cash sources and uses: $1,803,200,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $1,279,700,000.00Beginning cash$1.28 BEnding cash: Cash, cash equivalents, and restricted cash: $1,803,200,000.00Ending cash$1.80 BCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$205.60 MOperating cash − cash spent on PP&ECash flow / Net income0.94×Operating cash flow ÷ net incomeNet cash change+$523.50 MEnding cash − beginning cash
Chart details

United Therapeutics Corporation cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
1,279,700,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
313,600,000 US dollars. Net cash provided.
Net income
333,000,000 US dollars
Depreciation and amortization
24,200,000 US dollars
Share-based compensation expense
43,400,000 US dollars
Other
24,800,000 US dollars
Accounts receivable
1,700,000 US dollars
Inventories
negative 17,700,000 US dollars
Accounts payable and accrued expenses
negative 4,000,000 US dollars
Other assets and liabilities
negative 104,100,000 US dollars
Net unrealized losses on equity securities
negative 13,400,000 US dollars
Deferred income taxes
25,700,000 US dollars
Impairment of property, plant, and equipment
0 US dollars
Investing activities
87,500,000 US dollars. Net cash provided.
Purchases of property, plant, and equipment
negative 108,000,000 US dollars
Deposits
negative 700,000 US dollars
Purchases of available-for-sale debt securities
negative 69,100,000 US dollars
Maturities of available-for-sale debt securities
265,300,000 US dollars
Sales of available-for-sale debt securities
0 US dollars
Purchase of investment in privately held company
0 US dollars
Financing activities
122,400,000 US dollars. Net cash provided.
Payments to repurchase common stock
0 US dollars
Proceeds from line of credit
0 US dollars
Repayment of line of credit
0 US dollars
Excise tax paid on net share repurchase
0 US dollars
Payments of debt issuance costs
negative 3,400,000 US dollars
Proceeds from the exercise of stock options
126,300,000 US dollars
Proceeds from the issuance of stock under ESPP
0 US dollars
RSUs withheld for taxes
negative 500,000 US dollars
Operating adjustment reconciliation
139,200,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
126,300,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
265,300,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
1,803,200,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
1,803,200,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
523,500,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.94×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
313,600,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
108,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
205,600,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $313.60M of net income directly to operating cash and $19.40M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 313,600,000 US dollars minus 108,000,000 US dollars equals 205,600,000 US dollars.
United Therapeutics Corporation (UTHR) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!